By IDSE News Staff
Swissmedic approved artemether-lumefantrine (Coartem Baby, Novartis) as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet Baby in some countries, was developed with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.
The Swissmedic approval is based on the phase 2/3 CALINA study, which investigated a new ratio and dose of artemether-lumefantrine to account for metabolic differences in